(4-Chlorophenyl)(1-{-2-[(2,5-difluorobenzyl)amino]ethyl}-4-piperidinyl)methanone | 298697-69-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4-Chlorophenyl)(1-{-2-[(2,5-difluorobenzyl)amino]ethyl}-4-piperidinyl)methanone
• 英文别名: (4-Chlorophenyl)-[1-[2-[(2,5-difluorophenyl)methylamino]ethyl]piperidin-4-yl]methanone
• CAS: 298697-69-5
• 化学式: C₂₁H₂₃ClF₂N₂O
• 分子量: 392.876
• InChiKey: BZZQZDAWAXXDRW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans
  申请人：——

  公开号：US20030162753A1

  公开（公告）日：2003-08-28

  The compounds of formula (I) are hydrophilic aryl phosphate, thiophosphate, and aminophosphate intestinal apical membrane Na-mediated phosphate co-transportation inhibitors. The compounds can be administered orally, where they act to inhibit Na-dependent phosphate uptake in the intestines, or internally, where they interact with the phosphate control functions of the kidneys and parathyroid. They are useful for inhibiting sodium-mediated phosphate uptake, reducing serum PTH, calcium, calcitriol, and phosphate, and treating renal disease in an animal, including a human.

  化合物的化学式（I）为亲水性芳基磷酸酯、硫代磷酸酯和氨基磷酸酯，是肠道顶端膜Na介导的磷酸盐共同运输抑制剂。这些化合物可以经口服给药，在肠道中起到抑制Na依赖性磷酸盐摄取的作用，或者内部给药，在肾脏和甲状旁腺的磷酸盐控制功能中发挥作用。它们可用于抑制钠介导的磷酸盐摄取，降低血清PTH、钙、钙三醇和磷酸盐，治疗动物（包括人类）的肾脏疾病。
• Novel compounds
  申请人：AstraZeneca AB, a Sweden corporation

  公开号：US20030134840A1

  公开（公告）日：2003-07-17

  The invention provides compounds of general formula 1 wherein R 1 , m, Q, T, n, R 2 , R 3 , V, W, X and R 4 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了一般式1的化合物，其中R1、m、Q、T、n、R2、R3、V、W、X和R4在说明书中定义，其制备方法，包含它们的制药组合物以及它们在治疗中的应用。
• Inhibitors of intestinal apical membrane Na/phosphate co-transportation
  申请人：——

  公开号：US20020133036A1

  公开（公告）日：2002-09-19

  The compounds of formula (I) are hydrophilic aryl phosphate, thiophosphate, and aminophosphate intestinal apical membrane Na-mediated phosphate co-transportation inhibitors. The compounds can be administered orally, where they act to inhibit Na-dependent phosphate uptake in the intestines, or internally, where they interact with the phosphate control functions of the kidneys and parathyroid. They are therefore useful for inhibiting sodium-mediated phosphate uptake, reducing serum PTH, calcium, calcitriol, and phosphate, and treating renal disease in an animal, including a human.

  式（I）的化合物是亲水性芳基磷酸酯、硫代磷酸酯和氨基磷酸酯肠道顶端膜Na介导的磷酸共运输抑制剂。这些化合物可通过口服给药，在肠道内起到抑制依赖Na的磷酸摄取的作用，或在体内与肾脏和甲状旁腺的磷酸控制功能相互作用。因此，它们对于抑制钠介导的磷酸摄取、降低血清PTH、钙、活性维生素D和磷酸盐，以及治疗动物（包括人类）的肾脏疾病非常有用。
• NOVEL COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1165545A1

  公开（公告）日：2002-01-02
• JP2002540204A
  申请人：——

  公开号：JP2002540204A

  公开（公告）日：2002-11-26